Press Release: Pharnext provides regulatory and clinical update on PXT3003 Phase III study for the treatment of Charcot-Marie-Tooth Type 1A
BCL, NTX, SRB and their mix (PXT3003) down-regulate Pmp22 mRNA... | Download Scientific Diagram
CMT1A Clinical Trial Update: Pharnext PREMIER trial of PXT3003
Run 4 CMT: Update Pharnext PXT 3003 Clinical Trial
Charcot-Marie-Tooth Treatment: CMT - ABC30 Fresno
Daily oral treatment of CMT1A rats with PXT3003 down-regulates Pmp22... | Download Scientific Diagram
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) | PLOS ONE
Pharnext - PXT3003
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
PXT3003 therapy acting on Pmp22 overexpression and downstream... | Download Scientific Diagram
Pharnext - PXT3003
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
Pharnext - PXT3003
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
Pharnext - PXT3003
Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats - Prukop - 2020 - Journal of Neuroscience Research - Wiley Online Library
An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A | Orphanet Journal of Rare Diseases
A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A | Orphanet Journal of Rare Diseases | Full Text
Pharnext - PXT3003
Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A) | PLOS ONE
Response to PXT3003 on clinical scales (Full Analysis Set, n = 80).... | Download Scientific Diagram
Interim Analysis from the Ongoing Open-Label Phase III
PDF) A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
